LL-37: Risks & Legal Status

Critical Safety Information#

LL-37 is a research compound that has not been approved for human use by any major regulatory agency. This page provides risk information for educational purposes only.

Growth Factor and Angiogenesis Risks#

We summarize the specific safety risks of LL‑37 across three domains: growth factor/angiogenesis and tumor‑promotion concerns; immune modulation risks; and peptide sourcing/quality‑control issues.

Growth factor, angiogenesis, and tumor‑promotion risks

• EGFR/HB‑EGF transactivation and cell proliferation: LL‑37 promotes HB‑EGF shedding and transactivates EGFR, driving MAPK/PI3K signaling that increases keratinocyte and epithelial migration and proliferation in vitro and in wound‑healing models, raising concerns for growth‑factor–like activity in tissues. Reviews and experimental studies identify EGFR/ErbB engagement by LL‑37 in cancer contexts as well.
• FPR2‑dependent angiogenesis/arteriogenesis: LL‑37 is a potent FPR2 agonist that elicits Gαi‑dependent ERK/NF‑κB/ROS pathways; in vivo, FPR2 blockade or MEK inhibition reduces LL‑37‑induced angiogenesis/arteriogenesis, indicating pro‑angiogenic potential.
• VEGF axis induction in epithelial cells: LL‑37 alone induces VEGFA and PTGS2 in keratinocytes via scavenger receptors and partially via FPR2, supporting risk of pro‑angiogenic signaling in skin.
• Tumor cell proliferation/invasion and stromal recruitment: LL‑37 is upregulated in several cancers and can promote proliferation, invasion, chemotaxis, MMP expression, and recruit mesenchymal stromal cells that secrete pro‑tumor cytokines, collectively enhancing tumor progression in model systems. LL‑37 also increases MMP‑2/‑9 and uPA in epithelial models, facilitating matrix remodeling and invasion.
• EGFR/HER2–PI3K–Akt activation and metastasis in HCC: Overexpression of hCAP18/LL‑37 in hepatocellular carcinoma activates EGFR/HER2 and PI3K/Akt pathways, enhancing proliferation, EMT, migration, and metastasis in vitro and in xenografts, suggesting tumor‑promotion risk in this setting.

Immune modulation and autoimmunity risks

• Potentiation of nucleic‑acid sensing and type I IFN: LL‑37 binds self‑DNA/RNA, stabilizes these ligands, and promotes endosomal delivery to TLR7/8/9, leading to robust type I interferon and pro‑inflammatory cytokine responses in plasmacytoid dendritic cells, neutrophils, and keratinocytes. This mechanism is implicated in psoriatic inflammation and autoimmunity. LL‑37 also facilitates CpG‑ODN entry to endosomes, modulating TLR9 responses.
• NET‑driven inflammatory amplification: LL‑37 is a component of neutrophil extracellular traps (NETs); RNA–LL‑37 complexes fuel NETosis and create a self‑amplifying inflammatory loop in psoriasis patient neutrophils, increasing cytokines such as IL‑8, TNF, and IL‑1β.
• Keratinocyte innate activation: LL‑37 uptake via scavenger receptors (SCARB1, OLR1, AGER) induces type I IFN genes, VEGFA, and PTGS2 in keratinocytes, linking LL‑37 to concurrent pro‑inflammatory and pro‑angiogenic programs in skin.

Peptide sourcing and quality‑control risks

• Endotoxin (LPS) contamination: Cationic AMPs, including LL‑37, bind LPS; co‑purified endotoxin can confound bioassays and spuriously elevate inflammatory readouts if not rigorously removed and tested, necessitating stringent endotoxin control in production and analytics.
• Counterion effects (TFA vs chloride): Trifluoroacetate counterions commonly retained from solid‑phase synthesis can alter peptide aggregation, activity, and apparent cytotoxicity. Reviews recommend counterion exchange (e.g., to chloride) to reduce TFA‑associated artifacts, particularly for cationic helical AMPs such as LL‑37.
• Impurities, oxidation/aggregation, and stereochemical issues: Synthetic impurities, oxidized residues, and aggregates can increase cytotoxicity and variability; protease sensitivity and sequence/chirality modifications can shift safety profiles. Peptide translational literature emphasizes impurity profiling, anti‑aggregation strategies, and careful evaluation of D‑amino acid or other modifications to mitigate toxicity while maintaining activity.

Mitigation considerations include restricting systemic exposure, using delivery systems that localize peptide, monitoring angiogenesis‑related biomarkers, avoiding use in patients with active autoimmune skin disease, and enforcing GMP controls for endotoxin, counterion exchange, impurity/oxidation limits, and stereochemical purity during peptide sourcing.

Regulatory and Legal Status#

Objective: Provide the current regulatory and legal status of LL-37 in major jurisdictions (US FDA, EU EMA, Australia TGA, UK MHRA, Canada), including any recent regulatory changes.

Summary of available evidence and limitations

• The available evidence retrieved consists of secondary scholarly reviews; no primary regulator records (FDA, EMA, TGA, MHRA, Health Canada) were obtained within the current evidence set. Therefore, the following is a partial answer that reports what the retrieved sources claim and clearly notes the need for primary confirmation.

LL-37 regulatory status claims across jurisdictions

Interpretation and synthesis

• USA (FDA): One 2025 review article claims LL-37 has FDA approval for wound healing indications; however, an earlier 2019 review described LL-37 as being in Phase IIb development without approval. Without primary FDA documentation, the claimed approval cannot be verified here and should be treated as unconfirmed pending direct FDA database confirmation.
• EU (EMA): The same 2025 review claims EMA approval for wound healing, but no EMA primary record was retrieved; treat this claim as unconfirmed pending verification in EMA’s public assessment reports or Union Register.
• Australia (TGA): No retrieved evidence indicates a TGA approval or entry; status remains unknown from the current sources and requires TGA ARTG database verification.
• UK (MHRA): No retrieved evidence indicates MHRA authorization; status remains unknown from the current sources and requires UK PL/PLGB register or device/drug authorization check.
• Canada (Health Canada): No retrieved evidence indicates a Health Canada authorization; status remains unknown from current sources and requires the Drug Product Database/Notice of Compliance check.

Recent regulatory changes (2023–2026)

• The 2025 review asserts approvals in the USA and EU but does not document dates, product names, or regulatory identifiers, and thus cannot substantiate a specific 2023–2026 regulatory change. No other retrieved documents provided regulator notices, enforcement actions, reclassifications, or labeling changes for LL-37 in 2023–2026.

What to verify next (recommended primary checks)

• FDA: Drugs@FDA/Orange Book, Biological License Applications, and press releases for any LL-37 product names or synonyms.
• EMA: Union Register of medicinal products and EPARs for LL-37 or brand names; check CAT/ATMP opinions if applicable.
• TGA: Australian Register of Therapeutic Goods (ARTG) for LL-37 entries.
• MHRA (UK): Public Medicines Information (PL/PLGB), MHRA Product Information portal.
• Health Canada: Drug Product Database and Notice of Compliance database for LL-37.

Conclusion

• Based on current retrieved secondary evidence, some literature claims LL-37 holds approvals for wound healing in the USA and EU; however, these claims remain unverified in primary regulator sources and conflict with earlier literature describing LL-37 as investigational. No evidence was found for approvals in Australia, the UK, or Canada within the current set. Primary regulator verification is required to confirm the current regulatory and legal status and any recent changes.

At-Risk Populations#

Objective Identify which populations are at highest risk when using LL-37, focusing on pregnancy, cancer, immunocompromised individuals, and those on anticoagulants. We summarize human, animal, and mechanistic data specific to LL-37; when only related AMP evidence exists, we state this explicitly.

Summary table

Pregnancy. Direct interventional safety data for exogenous LL-37 in pregnancy are lacking. Placenta and trophoblast express cathelicidin under vitamin D control, and dysregulation is described in preeclampsia biology, indicating that LL-37 is an active immune mediator at the maternal–fetal interface (mechanistic/observational). Reviews of host defense peptides emphasize LL-37’s potent immunomodulation in barrier tissues, supporting plausibility that altering LL-37 levels could perturb trophoblast signaling. Although not LL-37, a cationic AMP surrogate (magainin) disrupted implantation/early placentation and altered trophoblast cytokines in primate and in vitro models, signaling class risks for cationic AMPs in early pregnancy (animal/in vitro). Taken together, pregnancy should be considered a high‑caution population, particularly in early gestation, pending dedicated safety studies.

Cancer patients. Multiple lines of evidence indicate pro‑tumor roles for LL‑37 in certain malignancies. In ovarian cancer, tumor LL‑37 recruits mesenchymal stromal cells via FPRL1, supports angiogenic stroma, enhances invasion, and is linked to immunosuppressive Treg recruitment (in vitro/tumor correlations). Reviews further associate LL‑37 with a metastatic phenotype in breast cancer and as a growth factor in lung cancer; myeloid cell–derived LL‑37 can drive lung cancer growth via Wnt/β‑catenin signaling (reviews/mechanistic). LL‑37 is a constituent of neutrophil extracellular traps (NETs), and NETs broadly support tumor progression and thrombosis in cancer patients (review). Overall, patients with active cancer—especially tumors known to exploit LL‑37 pathways—are at higher risk for pro‑tumor effects with exogenous LL‑37; use should be avoided or restricted to clinical trials.

Immunocompromised individuals. LL‑37 modulates neutrophil function: it can reduce excessive cytokine release while enhancing bacterial killing (human neutrophils) and endogenous cathelicidin deficiency impairs antimicrobial activity (mouse), suggesting potential benefit against infection. In sepsis models, adjunctive LL‑37 reduced lethality and inflammation, but post‑translational modifications (e.g., citrullination) can abrogate protective anti‑endotoxic functions, highlighting context dependence (reviews/animal). Given LL‑37’s capacity to also fuel autoimmunity via self‑nucleic acid complexes, immunocompromised states with dysregulated immunity warrant balanced caution and supervised use only in trials.

Those on anticoagulants / thrombosis risk. LL‑37 is a component of NETs. NETs activate coagulation, recruit platelets, and scaffold thrombi; NET‑mediated immunothrombosis is implicated in inflammatory diseases and cancer (reviews). While there is no direct evidence of pharmacokinetic or pharmacodynamic interactions between LL‑37 and heparin/warfarin/DOACs in humans, any intervention that augments NET formation or activity could increase thrombotic risk even under anticoagulation. Accordingly, people with high baseline thrombosis risk or already on anticoagulants should be considered at increased risk and monitored closely if LL‑37 is used.

Clinical context and gaps. A small, early‑phase intratumoral LL‑37 trial in melanoma exists, but broader human safety data in these populations are sparse; no pregnancy or anticoagulant interaction trials were identified (registry context) (NCT02225366 not citable by id here). The weight of evidence is mechanistic and preclinical; therefore, conclusions should be applied with caution and preference for clinical trial settings.

Ranking of highest‑risk populations

• Cancer patients: highest risk given consistent pro‑tumor mechanisms (MSC/Treg recruitment, angiogenesis, invasion) and NET‑linked progression/thrombosis.
• People on anticoagulants or with thrombosis risk: high risk due to NET‑driven coagulation and lack of known mitigating interactions with anticoagulants.
• Pregnancy: high caution/unknown, with plausible mechanistic risk at the maternal–fetal interface and class warnings from cationic AMPs; avoid especially in early gestation pending data.
• Immunocompromised: mixed; potential benefit in infection control but risk of dysregulated inflammation and loss of protective function in certain states; restrict to trials.

Practical guidance

• Avoid exogenous LL‑37 in active malignancy outside trials; if considered, assess tumor context for LL‑37 pathway exploitation and thrombotic risk.
• In pregnancy, especially first trimester, defer use until safety data exist; if unavoidable, ensure multidisciplinary oversight and rigorous monitoring.
• In immunocompromised/septic patients, consider only within controlled protocols with close immune and infection monitoring.
• In patients on anticoagulants or with prothrombotic conditions, weigh NET‑mediated thrombosis risk; monitor coagulation parameters and clinical events if LL‑37 is used.

Risk Mitigation#

For Researchers#

1. Use only from verified, third-party tested sources
2. Follow proper handling and sterility protocols
3. Document all observations carefully
4. Report adverse events

General Precautions#

1. Consult healthcare providers before any use
2. Start with lowest suggested amounts in research protocols
3. Monitor for any adverse effects
4. Discontinue immediately if problems arise

Related Reading#

• LL-37 overview and research guide
• LL-37 side effects profile
• LL-37 research evidence